Wang L et al. The Bruton’s tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): Preliminary results of a Phase II trial. Proc ASH 2011;Abstract 442.

Rule S et al. The addition of rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL): Results of the randomised UK National Cancer Research Institute (NCRI) trial. Proc ASH 2011;Abstract 440.

Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.

Dr O'Connor is Professor of Medicine and Developmental Therapeutics and Director of the Center for Lymphoid Malignancies at Columbia University Medical Center in New York, New York.